Trial Profile
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 22 Nov 2023 Planned End Date changed from 1 May 2021 to 1 Apr 2024.
- 29 Sep 2021 Results of an analysis assessing duration of follow-up and the detailed genetic and molecular characterization in unfit CLL patients published in the Blood
- 31 Aug 2017 Status changed from recruiting to active, no longer recruiting.